Can-Fite Bio falls on delay in psoriasis therapy study data

Can Fite Biopharma

08/03/2022 13:21

** U.S.-listed shares of Israeli biotech co  CANF.N  fall 8%
to $1.02 premarket
    ** CANF says it expects to report topline data from a
late-stage study of its experimental psoriasis therapy,
Piclidenoson, in Q2 instead of Q1  urn:newsml:reuters.com:*:nBw8btsdna
    ** Co cites an "unanticipated delay" in collection of data
from the study, which involved about 400 patients with
moderate-to-severe plaque psoriasis - an inflammatory skin
condition
    ** Piclidenoson is co's lead drug candidate, co is also
developing therapies for liver diseases and erectile dysfunction
    ** Stock down 13.2% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))